The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms

Summary

The purpose of this study is to investigate if minocycline limits the development of negative symptoms in early psychosis and to test via what mechanism of action this change occurs.

Conditions

• Schizophrenia and Disorders With Psychotic Features

Interventions

DRUG

Minocycline

Capsules containing 100mg minocycline (modified release), administered orally by the patient, two per day for the first two weeks and then three per day for the reminder of the 12 month treatment period in addition to standard therapy.

DRUG

Placebo

Matching placebo with appearance of over - encapsulated minocycline

Sponsors & Collaborators

• University of Edinburgh

  collaborator OTHER

• University of Cambridge

  collaborator OTHER

• University College, London

  collaborator OTHER

• University of Birmingham

  collaborator OTHER

• King's College London

  collaborator OTHER

• Manchester Mental Health & Social Care Trust

  collaborator OTHER_GOV

• Greater Manchester Mental Health NHS Foundation Trust

  collaborator OTHER

• Northern Care Alliance NHS Foundation Trust

  collaborator OTHER

• Lancashire Care NHS Foundation Trust

  collaborator NETWORK

• Cambridgeshire and Peterborough NHS Foundation Trust

  collaborator OTHER

• West London Mental Health NHS Trust

  collaborator OTHER

• North East London Foundation Trust

  collaborator OTHER

• Central and North West London NHS Foundation Trust

  collaborator OTHER

• Camden and Islington NHS Foundation Trust

  collaborator UNKNOWN

• South London and Maudsley NHS Foundation Trust

  collaborator OTHER

• NHS Lothian

  collaborator OTHER_GOV

• NHS Fife

  collaborator OTHER_GOV

• NHS Borders

  collaborator OTHER_GOV

• University Hospital Birmingham NHS Foundation Trust

  collaborator OTHER

• University of Manchester

  lead OTHER

Principal Investigators

• Bill Deakin, Professor · University of Manchester

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

16 Years

Max Age

35 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2013-02-28

Primary Completion

2016-05-31

Completion

2016-05-31